Lineage Cell Therapeutics Inc (LCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $231.35M
Last updated: Nov 17, 2026 at 11:06 AM ET
Lineage Cell Therapeutics Inc (LCTX) Earnings: Report Dates and Results
Lineage Cell Therapeutics (LCTX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Lineage Cell Therapeutics reported EPS of -$0.03, below the -$0.02 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LCTX has an expected report date of Mar 3, 2027.
LCTX Earnings Call
The latest LCTX earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 40 quarters below that had an estimate, LCTX beat 21, missed 14 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $1.43M, down 61.1% from $3.68M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.03 | -$0.02 | N/A | -50.00% | Miss | N/A | 4 | 0 up, 1 down | Nov 12, 2026 | $1.43M |
| Jun 30, 2026 | -$0.03 | -$0.03 | -$0.04 - -$0.02 | 0.00% | In line | N/A | 4 | 0 up, 1 down | Aug 6, 2026 | $1.07M |
| Mar 31, 2026 | -$0.03 | -$0.02 | -$0.03 - -$0.02 | -36.50% | Miss | N/A | 3 | 0 up, 1 down | May 12, 2026 | $1.73M |
| Dec 31, 2025 | $0.00 | -$0.04 | -$0.14 - -$0.02 | +108.75% | Beat | N/A | 6 | 0 up, 0 down | Mar 5, 2026 | $6.61M |
| Sep 30, 2025 | -$0.13 | -$0.03 | -$0.04 - -$0.02 | -333.33% | Miss | N/A | 6 | 1 up, 2 down | Nov 6, 2025 | $3.68M |
| Jun 30, 2025 | -$0.13 | -$0.03 | -$0.04 - -$0.02 | -333.33% | Miss | N/A | 6 | 1 up, 0 down | Aug 12, 2025 | $2.77M |
| Mar 31, 2025 | -$0.02 | -$0.03 | -$0.04 - -$0.02 | +33.33% | Beat | N/A | 5 | 2 up, 0 down | May 13, 2025 | $1.50M |
| Dec 31, 2024 | -$0.01 | -$0.03 | -$0.04 - -$0.02 | +66.67% | Beat | N/A | 4 | 1 up, 0 down | Mar 10, 2025 | $2.87M |
| Sep 30, 2024 | -$0.02 | -$0.03 | -$0.04 - -$0.03 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2024 | $3.78M |
| Jun 30, 2024 | -$0.03 | -$0.04 | -$0.05 - -$0.04 | +25.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | $1.41M |
| Mar 31, 2024 | -$0.04 | -$0.04 | -$0.05 - -$0.02 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 9, 2024 | $1.44M |
| Dec 31, 2023 | -$0.03 | -$0.04 | -$0.09 - $0.00 | +25.00% | Beat | N/A | 7 | 0 up, 1 down | Mar 7, 2024 | $2.09M |
| Sep 30, 2023 | -$0.04 | -$0.03 | -$0.07 - -$0.03 | -33.33% | Miss | N/A | 7 | 0 up, 0 down | Nov 9, 2023 | $1.25M |
| Jun 30, 2023 | -$0.03 | -$0.04 | -$0.07 - -$0.03 | +25.00% | Beat | N/A | 7 | 0 up, 0 down | Aug 10, 2023 | $3.23M |
| Mar 31, 2023 | -$0.03 | -$0.05 | -$0.07 - -$0.03 | +40.00% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2023 | $2.39M |
| Dec 31, 2022 | -$0.03 | -$0.04 | -$0.05 - -$0.03 | +25.00% | Beat | N/A | 7 | 0 up, 0 down | Mar 9, 2023 | $1.92M |
| Sep 30, 2022 | -$0.03 | -$0.04 | -$0.06 - -$0.02 | +25.00% | Beat | N/A | 8 | 0 up, 0 down | Nov 10, 2022 | $3.00M |
| Jun 30, 2022 | -$0.04 | -$0.02 | -$0.11 - -$0.01 | -100.00% | Miss | N/A | 7 | 0 up, 0 down | Aug 11, 2022 | $4.55M |
| Mar 31, 2022 | -$0.04 | -$0.06 | -$0.10 - $0.08 | +33.33% | Beat | N/A | 5 | 0 up, 0 down | May 12, 2022 | $5.24M |
| Dec 31, 2021 | -$0.17 | -$0.05 | -$0.06 - -$0.03 | -240.00% | Miss | -1800.0% | 6 | 0 up, 0 down | Mar 10, 2022 | $1.17M |
| Sep 30, 2021 | -$0.03 | -$0.05 | -$0.06 - -$0.04 | +40.00% | Beat | N/A | 5 | N/A | Nov 10, 2021 | $2.27M |
| Jun 30, 2021 | -$0.04 | -$0.04 | -$0.04 - -$0.03 | 0.00% | In line | N/A | 3 | N/A | Aug 12, 2021 | $512000 |
| Mar 31, 2021 | -$0.05 | -$0.04 | -$0.05 - -$0.03 | -25.00% | Miss | N/A | 3 | N/A | May 13, 2021 | $391000 |
| Dec 31, 2020 | $0.01 | -$0.05 | -$0.06 - -$0.04 | +120.00% | Beat | N/A | 5 | N/A | Mar 11, 2021 | $166000 |
| Sep 30, 2020 | -$0.04 | -$0.04 | -$0.05 - -$0.04 | 0.00% | In line | N/A | 2 | N/A | Nov 4, 2020 | $571000 |
| Jun 30, 2020 | -$0.03 | -$0.05 | -$0.05 - -$0.03 | +40.00% | Beat | N/A | 4 | N/A | Aug 6, 2020 | $386000 |
| Mar 31, 2020 | -$0.06 | -$0.03 | -$0.09 - -$0.03 | -100.00% | Miss | N/A | 5 | N/A | May 7, 2020 | $166000 |
| Dec 31, 2019 | -$0.03 | -$0.05 | -$0.07 - -$0.02 | +40.00% | Beat | N/A | 5 | N/A | Mar 12, 2020 | $1.24M |
| Sep 30, 2019 | -$0.05 | -$0.05 | -$0.06 - -$0.05 | 0.00% | In line | N/A | 3 | N/A | Nov 12, 2019 | $567000 |
| Jun 30, 2019 | -$0.06 | -$0.05 | N/A | -20.00% | Miss | N/A | N/A | N/A | Aug 8, 2019 | $779000 |
| Mar 31, 2019 | -$0.05 | -$0.06 | N/A | +16.67% | Beat | N/A | N/A | N/A | May 9, 2019 | $928000 |
| Dec 31, 2018 | -$0.32 | -$0.07 | N/A | -357.14% | Miss | N/A | N/A | N/A | Mar 14, 2019 | $758000 |
| Sep 30, 2018 | -$0.08 | -$0.06 | N/A | -33.33% | Miss | -125.8% | N/A | N/A | Nov 8, 2018 | $982000 |
| Jun 30, 2018 | -$0.07 | -$0.09 | N/A | +22.22% | Beat | N/A | N/A | N/A | Aug 2, 2018 | $2.55M |
| Mar 31, 2018 | -$0.10 | -$0.07 | N/A | -42.86% | Miss | N/A | N/A | N/A | May 10, 2018 | $701000 |
| Dec 31, 2017 | -$0.58 | -$0.07 | N/A | -728.57% | Miss | N/A | N/A | N/A | Mar 15, 2018 | $999000 |
| Sep 30, 2017 | $0.31 | -$0.08 | N/A | +487.50% | Beat | +3.3% | N/A | N/A | Nov 9, 2017 | $1.69M |
| Jun 30, 2017 | -$0.05 | -$0.09 | N/A | +44.44% | Beat | -119.2% | N/A | N/A | Aug 2, 2017 | $381000 |
| Mar 31, 2017 | -$0.07 | -$0.09 | N/A | +22.22% | Beat | N/A | N/A | N/A | May 10, 2017 | $390000 |
| Dec 31, 2016 | -$0.05 | -$0.14 | N/A | +64.29% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $1.08M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.28, after -$0.10 the year before. It was $0.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.28 | N/A |
| Dec 31, 2024 | -$0.10 | N/A |
| Dec 31, 2023 | -$0.13 | N/A |
| Dec 31, 2022 | -$0.14 | N/A |
| Dec 31, 2021 | -$0.29 | N/A |
| Dec 31, 2020 | -$0.12 | N/A |
| Dec 31, 2019 | -$0.19 | N/A |
| Dec 31, 2018 | -$0.57 | N/A |
| Dec 31, 2017 | -$0.39 | -221.9% |
| Dec 31, 2016 | $0.32 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 7,900 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 7,940 | 8 | |
| 2025Q4 | Dec 31, 2025 | 8,256 | 9 | |
| 2025Q3 | Sep 30, 2025 | 8,309 | 10 | |
| 2025Q2 | Jun 30, 2025 | 7,325 | 9 | |
| 2025Q1 | Mar 31, 2025 | 7,255 | 9 | |
| 2024Q3 | Sep 30, 2024 | 9,173 | 11 |
2026Q1 Earnings Call
Opening remarks
Ioana C. Hone Head of Investor Relations Thank you, Demi. Good afternoon, and thank you for joining us. A press release reporting our first quarter 2026 financial results was issued earlier today, 05/12/2026, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statements sections in today's press release and in the company's SEC filings including its most recent annual report on Form 10 and in the Form 10-Q filed today. We caution you not to place undue reliance on any forward-looking statements which speak only as of today, and are qualified by the cautionary statements and risk factors described in our SEC filings. With us today are Brian Culley, our Chief Executive Officer, and Jill Ann Howe, our Chief Financial Officer. I will now hand the call over to Brian.
Brian Culley Chief Executive Officer Thank you, Ioana, and good afternoon, everyone. We appreciate you taking the time to join us today. We have a lot of great things to cover. I am going to try and keep it short so that we can have plenty of time for analyst questions. I do want to highlight the successful expansion of AlloSCOPE, our proprietary cell manufacturing platform, most notably because it led to the launch of COR1, our new wholly owned corneal endothelial cell transplant program. We also successfully met our first internal milestone with our ILT1 manufacturing initiative and established a new scientific advisory board and attracted a recognized, established cell therapy executive as its founding member. But before I share those and other updates, I will begin with the status of our lead clinical program, OpRegen. Data we reported several years ago from the OpRegen Phase 1/2a clinical study included improved anatomy of the retina, halting or reversal of atrophic progression, and improved vision in patients with dry AMD. These are compelling data because they are not known to occur naturally in human beings. Since we made these initial reports, two additional and very important advancements have occurred in the field. The first of these is that three other companies have reported similar results with their own version of an RPE transplant, independently providing further evidence in support of the mechanism and its treatment effects.
Frequently Asked Questions About LCTX
When is Lineage Cell Therapeutics's next earnings date?
Lineage Cell Therapeutics's next earnings report is expected for Mar 3, 2027.
Did LCTX beat earnings estimates last quarter?
No. Lineage Cell Therapeutics reported EPS of -$0.03 for the quarter ended Sep 30, 2026, below the -$0.02 estimate by 50.00%.
What EPS do analysts expect from LCTX next quarter?
The consensus EPS estimate for Lineage Cell Therapeutics for the quarter ending Dec 31, 2026 is $0.00 from 9 analysts, with estimates from -$0.04 to $0.08.
How often does LCTX beat earnings estimates?
Lineage Cell Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -68.05%.
LCTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors